Oxford Cancer Analytics Raises $11M to Advance AI-Driven Blood Tests for Early Cancer Detection.

Oxford Cancer Analytics (OXcan), a UK and Canada-based medtech company, has raised $11 million in Series A funding. This latest oxford cancer analytics funding round supports the development of their innovative blood test for early cancer detection using advanced proteomics and AI.

The round was led by We Venture Capital and Cross-Border Impact Ventures, with support from Eka Ventures, Civilization Ventures, DigitalDx Ventures, Macmillan Cancer Support, Aurelium Ventures, OKG Capital, and several angel investors. This brings OXcan’s total funding to $16.7 million.

The investment will help OXcan move forward with the commercialization of its minimally invasive liquid biopsy blood test. The company focuses on lung cancer, the world’s leading cause of cancer-related deaths. Early detection dramatically improves patient outcomes.

Dr. Peter Jianrui Liu, CEO and co-founder of OXcan, said: “Using state-of-art proteomics and tailored AI approaches, OXcan is developing a blood test to enable earlier detection and treatments with curative intents, starting with lung cancer.”

Lung cancer is often diagnosed too late, with over 70% of cases caught beyond the localized stage. A 12-fold increase in five-year survival is possible when it is found at stage one compared to stage four. OXcan aims to change this with its cutting-edge approach.

The OXcan platform combines protein analysis with explainable machine learning. By narrowing thousands of proteins into key biomarker signatures, the company has significantly increased detection rates across several cancer types, according to a study in iScience.

With a patented platform and a growing team, OXcan operates in over 20 healthcare centers across three continents. The test is designed to be affordable, easy to use, and scalable to meet global demand.

Dr. Heinrich Roder has joined the team as SVP of R&D. He brings over 20 years of experience in liquid biopsy development and believes strongly in OXcan’s vision. “I feel privileged to join the team,” he said, “Together, our plan is to start a new era of early detection.”

Louise Warme, MD of We Venture Capital, said: “The power of the OXcan proteomics biomarker discovery platform and the data generated stand out. We are excited to support the company in this next growth phase.”

The company’s approach to liquid biopsy is unique in its focus on proteomics. Traditional blood-based tests often struggle with early-stage detection, but OXcan’s method offers broader protein analysis for better accuracy and localization.

Macmillan Cancer Support also backed this round. “OXcan’s simple, low cost and accurate blood test has the potential to make it easier to diagnose lung cancer,” said Felix Litzkow of Macmillan. “We’re proud to support projects that transform care.”

OXcan's test is built to integrate into current healthcare workflows. Dr. Daniel Szulc, Chief Product Officer, explained that the goal is to work with existing clinical pathways, making adoption and implementation more seamless for providers and patients.

Since its founding in 2020 by Dr. Liu and Dr. Andreas Halner, the company has made strong strides. The new oxford cancer analytics funding will allow the team to continue refining its technology and expand access to its test globally.

Chairman Brad Wilson, formerly of GlaxoSmithKline, said, “I have worked with OXcan’s founders since the seed round and have been impressed by the quality of their work. My investment in this round reflects my strong belief in their strategy and team.”

OXcan’s mission is clear—to provide reliable, early cancer detection through accessible technology. With this new backing, the company is positioned to bring its blood test to more people and transform cancer outcomes around the world.